Product Name:

NebuSelect™ Recombinant FITC-Compatible Human CD19, His-tag

Catalog#:

NBL-242969

Description:

NebuSelect™ Recombinant FITC-Compatible Human CD19, His-tag(Cat#NBL-242969) is expressed in HEK293 with His tag at the C-Terminus.It contains Pro20-Lys291.

Species:

Human

Expression System:

HEK293

Molecular Weight: 

The protein has a predicted MW of 60.1 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Bis-Tris PAGE result.

Target Name:

FITC-Compatible CD19; CD19; B4; CVID3; Leu-12; MGC12802

Target Information:

CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.

Amino Acid Sequence: 

Pro20-Lys291

Purity:

＞95%

Formulation:

see COA

Endotoxin:

＜1EU/ug(LAL Method)

Storage: 

4°C for short term. 

-20°C for long term.

To get more information, please contact us freely.